Physician profile
Mimi Yang
NPI 1659837250
$920.18
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $920.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $197.29 | 2021 | |
| Amgen INC. | $191.20 | 2021 | |
| Janssen Biotech, INC. | $118.37 | 2021 | |
| Lilly USA, LLC | $88.79 | 2021 | |
| Ucb, INC. | $67.27 | 2021 | |
| Aurinia Pharma U.S., INC. | $42.26 | 2021 | |
| Novartis Pharmaceuticals Corporation | $31.38 | 2021 | |
| Radius Health, INC. | $31.32 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.13 | 2021 | |
| Pfizer INC. | $25.62 | 2021 | |
| Bioventus LLC | $23.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.68 | 2021 | |
| Hikma Pharmaceuticals USA | $16.39 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $13.31 | 2021 | |
| Horizon Therapeutics Plc | $12.72 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12.45 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mimi Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.